Back to results
US 2017/0281728 A1Published application
Method for treating cancer using tetradrine
AssigneeBoard of Supervisors of Louisiana State University and Agricultural and Mechanical College
InventorHari K. KOUL
Life of this patent
Estimating the term…
Abstract
A method of treating a cancer disease or pre-disease condition in a mammal comprising administering a first pharmaceutical composition including a therapeutically effective amount of a first therapeutic, wherein the first therapeutic is tetrandrine, a tetrandrine derivative, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.
Claims14
A method of treating a cancer disease or pre-disease condition in a mammal comprising:
- administering a first pharmaceutical composition including a therapeutically effective amount of a first therapeutic;
- wherein the first therapeutic is tetrandrine, a tetrandrine derivative, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.
A therapeutic product comprising:
- a first pharmaceutically active agent being one of tetrandrine, a tetrandrine derivative, pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, and a combination thereof;
- and
- a second pharmaceutically active agent being one of TNF-related apoptosis-inducing ligand (TRAIL), tumor necrosis factor-alpha (TNF-α), and pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, and a combination thereof.
Dependencies are inferred from the claim text.